EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access

New Onset of Graves’ Orbitopathy Following Bendamustine-Rituximab (BR) therapy in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review

E D Kozlov, E G Bessmertnaya, S Sh Chandola, E I Yamashkina

Problems of Endocrinology · 20.05.2026 · 72 (2) · 13-22

DOI: 10.14341/probl13616 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Problems of Endocrinology, online erschienen am 20.05.2026. Verfasst von E D Kozlov und 3 weiteren Autor:innen. Beteiligte Einrichtung: Ogarev Mordovia State University. Hauptthemen laut MEDLINE: Rituximab, Leukemia, Lymphocytic, Chronic, B-Cell, Bendamustine Hydrochloride, Graves Ophthalmopathy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Graves’ orbitopathy (GO) is a progressive autoimmune disorder of visual organ, mostly associated with Graves’ disease (GD). Although rituximab has been used as an off-label therapy for steroid-resistant GO, paradoxical immune reactivation has also been reported. We present a rare case of GO that developed after bendamustine-rituximab (BR) therapy for chronic lymphocytic leukemia (CLL). A 73-year-old male with a 3-year history of GD, presented with new onset of bilateral proptosis, diplopia, and decreased visual acuity, that happened two weeks after his second BR cycle for CLL. The anamnesis was negative for both smoking, and radioiodine therapy. Laboratory studies showed persistently elevated thyrotropin receptor antibodies levels in plasma, and extraocular muscle enlargement on orbital MRI. The active phase (CAS 6/6) of moderate-to-severe (EUGOGO) GO was diagnosed. Despite two courses of intravenous methylprednisolone (cumulative dose — 12.2 g) and 10 retrobulbar dexamethasone injections, the patient progressed to dysthyroid optic neuropathy. Although the patient had a predisposing autoimmune background, the close temporal association with BR therapy, progressive disease course, and glucocorticoid resistance suggest that chemotherapy-induced immune dysregulation played a critical role in triggering GO. Rituximab-related B-cell depletion and cytokine release syndrome may have facilitated T-cell–mediated orbital inflammation, while bendamustine-induced lymphopenia further disrupted immune tolerance. This case illustrates the potential for paradoxical autoimmune activation following BR therapy in a predisposed patient. Clinicians should monitor for GO signs, and symptoms before, during, and after BR therapy in patients with underlying thyroid autoimmunity. Further clinical trials are needed to verify this phenomenon.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabLeukemia, Lymphocytic, Chronic, B-CellBendamustine HydrochlorideGraves OphthalmopathyAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAged

Substanzen

RituximabBendamustine Hydrochloride

Autor:innen und Institutionen

  • Ogarev Mordovia State University.
  • Endocrinology Research Centre.

Zitieren

APA

Kozlov, E. D., Bessmertnaya, E. G., Chandola, S. S., & Yamashkina, E. I. (2026). New Onset of Graves’ Orbitopathy Following Bendamustine-Rituximab (BR) therapy in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review. Problems of Endocrinology, 72(2), 13-22. https://doi.org/10.14341/probl13616

Vancouver

Kozlov ED, Bessmertnaya EG, Chandola SS, Yamashkina EI. New Onset of Graves’ Orbitopathy Following Bendamustine-Rituximab (BR) therapy in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review. Problems of Endocrinology. 2026;72(2):13-22. doi:10.14341/probl13616

BibTeX
@article{Kozlov2026,
  author = {Kozlov, E D and Bessmertnaya, E G and Chandola, S Sh and Yamashkina, E I},
  title = {New Onset of Graves’ Orbitopathy Following Bendamustine-Rituximab (BR) therapy in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review},
  journal = {Problems of Endocrinology},
  year = {2026},
  volume = {72},
  number = {2},
  pages = {13--22},
  doi = {10.14341/probl13616}
}
Kostenlos starten →